Search
Join your ACC colleagues and Peter Murphy to learn everything you wanted to know about the Corporate Transparency Act at this upcoming ACC Baltimore event. Learn about the new compliance obligations that the CTA imposes on both U.S. and foreign entities, how and when to comply and how to meet the...
With the close of summer, businesses across the United States are finally confronting the looming corporate disclosure requirements imposed by the Corporate Transparency Act (CTA) and the New York Corporate Transparency Act (NY CTA). These laws introduce stringent reporting obligations aimed at...
Saul Ewing LLP is proud to announce that Charles M. Lizza, Vice Chair of the firm’s Litigation Department, was named to the NJBIZ 2024 Law Power 50 list. This is the sixth year in a row that Mr. Lizza has been included on this list of the state's top lawyers. Professionals are selected for the list...
Introduction On June 18, 2024, the Federal Trade Commission (“FTC”) unanimously agreed to submit a comment supporting a recent proposed U.S. Patent and Trademark Office (“PTO”) rule that would mandate the disclosure of all settlement agreements made between parties appearing before the Patent Trial...
On April 23, 2024, the Federal Trade Commission (FTC) issued its proposed final rule (the “Rule”) banning the use of future noncompete agreements for all workers, including senior executives, 89 FR 38342. Noncompete agreements have long been a valuable tool in a company’s toolbox to mitigate the...
The decision of the Federal District Court for the Northern District of Alabama in the case of National Small Business United v. Yellen , announced on Friday, March 1, 2024, has created uncertainty for both reporting companies and their attorneys under the Corporate Transparency Act (“CTA”). What...
The federal Corporate Transparency Act (“CTA”) requires that corporations submit a report to the Financial Crimes Enforcement Network (“FinCEN”) before January 1, 2025, with information on the persons who exercise substantial control over the corporation. As currently in place, condominium and...
New requirements arising from the Corporate Transparency Act of 2019 took effect on Jan 1, 2024. If your small business is formed as an entity that meets the definition of a “Reporting Company” under the Act, your organization will have to report information about their beneficial owners, i.e., the...
January 26, 2024 - With AI poised to reshape the practice of law and businesses in every industry, Saul Ewing is pleased to partner with the ABA’s Intellectual Property Litigation Committee in forming the AI Subcommittee. The AI Subcommittee will monitor legal and technological developments in this...
For all “reporting companies” created or registered on or after January 1, 2024, information concerning the “beneficial owners” of the reporting company must be reported to the Financial Crimes Enforcement Network (“FinCEN”) along with information concerning “company applicants.” As a result, both...
A 2023 update on corporate litigation in the Delaware Court of Chancery, as well as an update on the annual amendments made to the General Corporation Law of the State of Delaware and alternative entity acts, which were all effective as of August 1, 2023. The material statutory amendments discussed...
Introduction The introduction to the final regulations issued under the Corporate Transparency Act (“CTA”) by the Financial Crimes Enforcement Network of the United States Treasury (“FinCEN”) states that, “[i]llicit actors frequently use corporate structures such as shell and front companies to...
“Company applicants” — the term may sound vague, but the identities of “company applicants” of reporting companies are just as important under the new federal Corporate Transparency Act (the “CTA”) as the identities of the beneficial owners of those companies. What You Need to Know: The era of...
On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...
If you are the owner or co-owner of a small to medium-size medical practice, dental practice, or other health care concern, you have probably never thought of your practice as the type of vehicle that can be used to launder money—not much revenue in the form of cash, too much regulatory oversight...